Kidney Cancer: An Overview of Current Therapeutic Approaches

Area of Science:

• Oncology
• Immunotherapy
• Genitourinary Cancers

Background:

• Metastatic renal cell carcinoma (RCC) management has significantly evolved with new treatment strategies.
• Immunotherapy-based combinations and targeted therapies (antiangiogenesis, immune checkpoint blockade) are now standard first-line treatments.
• Rising recurrence rates necessitate personalized treatment plans and predictive biomarkers for response.

Purpose of the Study:

• To review current first-line and second-line therapies for metastatic RCC.
• To highlight pivotal clinical trial data for existing and emerging treatments.
• To focus on ongoing adjuvant clinical trials, including novel agents, for improved patient outcomes.

Main Methods:

• Literature review of pivotal clinical trials and guidelines.
• Analysis of data for current first-line and second-line therapies in metastatic RCC.
• Examination of ongoing clinical trials in the adjuvant setting.

Main Results:

• First-line treatment landscape dominated by immunotherapy combinations and targeted agents.
• Significant progress in understanding treatment efficacy and adverse event profiles.
• Active research in the adjuvant setting exploring novel therapeutic agents.

Conclusions:

• Personalized treatment strategies and predictive biomarkers are crucial for managing metastatic RCC.
• Ongoing clinical trials, particularly in the adjuvant setting, hold promise for future therapeutic advancements.
• The evolving landscape requires continuous evaluation of novel agents and treatment combinations.